9804847-3
IPDS's
copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 209/18, 405/06, A61K 31/40

A1

(11) International Publication Number: WO 97/43260

(43) International Publication Date: 20 November 1997 (20.11.97)

(21) International Application Number: PCT/EP97/01882

(22) International Filing Date: 11 April 1997 (11.04.97)

(30) Priority Data:
9609641.7 9 May 1996 (09.05.96) GB

(71) Applicant *(for all designated States except GB US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: RAWSON, David, James [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DACK, Kevin, Neil [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DICKINSON, Roger, Peter [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). JAMES, Kim [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patents Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).


(81) Designated States: AU, BG, BR, CA, CN, CZ, HU, IL, IS, JP, KR, LK, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS

(57) Abstract

Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R^1 and R^2 are optional substituents and independently represent C_{1-6} alkyl, C_{2-6} alkenyl [optionally substituted by CO_2H or $CO_2(C_{1-6}$ alkyl)], C_{2-6} alkynyl, halogen, C_{1-3} perfluoroalkyl, $(CH_2)_mAr^1$, $(CH_2)_mHet^1$, $(CH_2)_mCONR^7R^8$, $(CH_2)_mCO_2R^8$, $O(CH_2)_qCO_2R^8$, $(CH_2)_mCOR^8$, $(CH_2)_mOR^8$, $O(CH_2)_pOR^8$, $(CH_2)_mNR^7R^8$, $CO_2(CH_2)_qNR^7R^8$, $(CH_2)_mCN$, $S(O)_nR^8$, $SO_2NR^7R^8$, $CONH(CH_2)_mAr^1$ or $CONH(CH_2)_mHet^1$; R^3 represents H, C_{1-6} alkyl, $(CH_2)_pNR^9R^{10}$, SO_2R^{10}, $SO_2NR^9R^{10}$, $(CH_2)_mCOR^{10}$, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_mCONR^9R^{10}$, $(CH_2)_mCO_2R^{10}$, $(CH_2)_pCN$, $(CH_2)_pR^{10}$ or $(CH_2)_pOR^{10}$; R^4 represents H or C_{1-6} alkyl; R^5 represents H or OH; R^6 represents phenyl optionally fused to a heterocyclic ring, the group as a whole being optionally substituted; R^{7-10} are fully defined herein and may independently represent Ar^2 or Het^2; Z represents CO_2H, CONH(tetrazol-5-yl), $CONHSO_2O(C_{1-4}$ alkyl), CO_2Ar^3, $CO_2(C_{1-6}$ alkyl), tetrazol-5-yl, $CONHSO_2Ar^3$, $CONHSO_2(CH_2)_qAr^3$ or $CONHSO_2(C_{1-6}$ alkyl); Ar^{1-3} independently represent phenyl, naphthyl, or an aromatic heterocycle, which groups are optionally fused and optionally substituted; and Het^1 and Het^2 independently represent a non-aromatic heterocycle which is optionally substituted; are useful in the treatment of restenosis, renal failure and pulmonary hypertension.



(I)